Feb 9 (Reuters) - Intellipharmaceutics International Inc IPCI.TO :
* INTELLIPHARMACEUTICS MEETS WITH FDA REGARDING OXYCODONE ER NDA DEVELOPMENT PROGRAM
* INTELLIPHARMACEUTICS INTERNATIONAL - BASED ON MEETING WITH FDA, OXYCODONE ER WILL NO LONGER INCLUDE THE BLUE DYE IN IT
* INTELLIPHARMACEUTICS INTERNATIONAL- FDA CONFIRMED REMOVAL OF BLUE DYE IN OXYCODONE ER UNLIKELY TO HAVE IMPACT ON ITS FORMULATION QUALITY, PERFORMANCE
* INTELLIPHARMACEUTICS INTERNATIONAL - WILL NOT BE REQUIRED TO REPEAT IN VIVO BIOEQUIVALENCE STUDIES & PHARMACOKINETIC STUDIES SUBMITTED IN OXYCODONE ER NDA
* INTELLIPHARMACEUTICS - FDA SAID, FROM ABUSE LIABILITY PERSPECTIVE,CATEGORY 1 STUDIES WILL NOT HAVE TO BE REPEATED ON OXYCODONE ER WITHOUT BLUE DYE